Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2025-12-25 @ 3:32 AM
NCT ID:
NCT00280605
Eligibility Criteria:
Inclusion Criteria:
* Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
Exclusion Criteria:
* Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12 following months
* Patients previously not improved by an alpha 1-blocker treatment
* Patients whose urinary symptoms are satisfactorily controlled on other Benign Prostatic Hyperplasia medication (alpha 1-blockers and 5-ARI)
* Known hypersensitivity to alfuzosin
* History of postural hypotension or syncope
* Combination with other alpha 1-blockers
* Hepatic insufficiency
* Unstable angina pectoris
* Severe concomitant condition threatening life
Healthy Volunteers:
False
Sex:
MALE
Study:
NCT00280605
Study Brief:
Protocol Section:
NCT00280605